NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
01 mars 2024 16h04 HE
|
NurExone Biologic Inc
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
NurExone’s Intellectual Property Portfolio Expands
20 févr. 2024 16h05 HE
|
NurExone Biologic Inc
NurExone's Intellectual Property portfolio is expanding to encompass processes and compositions related to exosomes in large-scale production
NurExone Launches Licensing Efforts for ExoTherapy Platform
14 févr. 2024 16h20 HE
|
NurExone Biologic Inc
NurExone Biologic launches licensing efforts for its ExoTherapy platform for creating nanodrugs by loading therapeutic molecular cargo into exosomes.
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant
02 févr. 2024 16h05 HE
|
NurExone Biologic Inc
Nurexone Biologic Initiates European Orphan Drug Designation Process Following U.S. Grant for its groundbreaking ExoPTEN product
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
17 janv. 2024 08h34 HE
|
NurExone Biologic Inc
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
05 janv. 2024 08h30 HE
|
NurExone Biologic Inc
NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million
NurExone Biologic Extends Spinal Cord Injury Therapy Portfolio With New RNA Sequences Promoting Healing and Regeneration
29 nov. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone Biologic expands its portfolio of products to address spinal cord injuries & neuron regeneration in CNS indications
NurExone Reports Third Quarter 2023 Financial Results and Provides Corporate Update
24 nov. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone released a corporate update and reported financial results for the quarter ended September 30, 2023.
NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment
30 oct. 2023 09h20 HE
|
NurExone Biologic Inc
NurExone Biologic Receive FDA Orphan-Drug Designation to its ExoPTEN Therapy for Acute Spinal Cord Injury Treatment
Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee
19 oct. 2023 08h30 HE
|
NurExone Biologic Inc
NurExone Biologic welcomes Prof. Teodoro Forcht Dagi, a renowned neurosurgeon and life science venture capitalist, to its Scientific Advisory Board.